KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Expenses (2016 - 2025)

Sarepta Therapeutics has reported Operating Expenses over the past 15 years, most recently at $854.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $854.5 million for Q4 2025, up 72.03% from a year ago — trailing twelve months through Dec 2025 was $2.9 billion (up 72.1% YoY), and the annual figure for FY2025 was $2.9 billion, up 72.1%.
  • Operating Expenses for Q4 2025 was $854.5 million at Sarepta Therapeutics, up from $502.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for SRPT hit a ceiling of $1.0 billion in Q1 2025 and a floor of $223.9 million in Q3 2021.
  • Median Operating Expenses over the past 5 years was $375.4 million (2023), compared with a mean of $436.2 million.
  • Biggest five-year swings in Operating Expenses: fell 20.33% in 2021 and later soared 176.11% in 2025.
  • Sarepta Therapeutics' Operating Expenses stood at $307.3 million in 2021, then rose by 18.87% to $365.3 million in 2022, then rose by 1.89% to $372.2 million in 2023, then skyrocketed by 33.47% to $496.7 million in 2024, then soared by 72.03% to $854.5 million in 2025.
  • The last three reported values for Operating Expenses were $854.5 million (Q4 2025), $502.7 million (Q3 2025), and $495.5 million (Q2 2025) per Business Quant data.